Video

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma

Author(s):

Giovanni Grignani, MD

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.

This is a new option that oncologists should consider for frail patients who have soft tissue sarcoma.

Related Videos
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Related Content
2rogan – stock.adobe.com
November 12th 2024

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

Gina Z. D’Amato, MD
February 9th 2023

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

Fixed-Dose CAR T Cells and UB-TT170 in R/R Osteosarcoma | Image Credit: © MdBabul - stock.adobe.com
November 11th 2024

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors
December 29th 2022

Somaiah Shares Insight on the Changing Landscapes of GIST, TGCT, and RAS/RAF-Mutant Tumors

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 2nd 2024

The OncFive: Top Oncology Articles for the Week of 10/27

ESMO 2024
November 1st 2024

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes